COVID -19 associated candidemia: from a shift in fungal epidemiology to a rise in azole drug resistance.

Candida parapsilosis ERG11 Azole resistance COVID-19-associated candidemia Y132F

Journal

Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835

Informations de publication

Date de publication:
23 Mar 2024
Historique:
medline: 24 3 2024
pubmed: 24 3 2024
entrez: 24 3 2024
Statut: aheadofprint

Résumé

Our understanding of fungal epidemiology and the burden of antifungal drug resistance in COVID-19-associated candidemia (CAC) patients is limited. Therefore, we conducted a retrospective multicenter study in Iran to explore clinical and microbiological profiles of CAC patients. Yeast isolated from blood, were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and subjected to antifungal susceptibility testing (AFST) using the broth microdilution method M27-A3 protocol. A total of 0.6% of the COVID-19 patients acquired CAC (43/6174). Fluconazole was the most widely used antifungal, and 37% of patients were not treated. Contrary to historic candidemia patients, C. albicans and C. tropicalis were the most common species. In vitro resistance was high and only noted for azoles; 50%, 20%, and 13.6% of patients were infected with azole-non-susceptible (ANS) C. tropicalis, C. parapsilosis, and C. albicans isolates, respectively. ERG11 mutations conferring azole resistance were detected for C. parapsilosis isolates (Y132F), recovered from an azole-naïve patient. Our study revealed an unprecedented rise in ANS Candida isolates, including the first C. parapsilosis isolate carrying Y132F, among CAC patients in Iran, which potentially threatens the efficacy of fluconazole, the most widely used drug in our centers. Considering the high mortality rate and 37% of untreated CAC cases, our study underscores the importance of infection control strategies and antifungal stewardship to minimize the emergence of ANS Candida isolates during COVID-19. The mortality rate for patients with COVID-19-associated candidemia (CAC) is high. Fluconazole was the most widely used antifungal but candidemia with azole-non-susceptible Candida species are increasing.

Autres résumés

Type: plain-language-summary (eng)
The mortality rate for patients with COVID-19-associated candidemia (CAC) is high. Fluconazole was the most widely used antifungal but candidemia with azole-non-susceptible Candida species are increasing.

Identifiants

pubmed: 38521982
pii: 7634360
doi: 10.1093/mmy/myae031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Auteurs

Mohammad Javad Najafzadeh (MJ)

Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Tahmineh Shaban (T)

Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Hossein Zarrinfar (H)

Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Alireza Sedaghat (A)

Lung Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Neginsadat Hosseinikargar (N)

Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Fariba Berenji (F)

Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mahsa Jalali (M)

Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Michaela Lackner (M)

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.

Jasper Elvin James (JE)

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.

Macit Ilkit (M)

Division of Mycology, Faculty of Medicine, Çukurova University, Adana, Turkey.

Cornelia Lass-Flörl (C)

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.

Classifications MeSH